Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.–10. rezultāts no 100.
45. lappuse
... ment of boils cannot be considered gen- erally recognized as safe and effective . ( b ) Any OTC drug product that is la- beled , represented , or promoted for the treatment of boils is regarded as a new drug within the meaning of ...
... ment of boils cannot be considered gen- erally recognized as safe and effective . ( b ) Any OTC drug product that is la- beled , represented , or promoted for the treatment of boils is regarded as a new drug within the meaning of ...
49. lappuse
... ment of hypophosphatemia . ( a ) Hypophosphatemia is a condition in which an abnormally low plasma level of phosphate occurs in the blood . This condition is not amenable to self- diagnosis or self - treatment . Treatment of this ...
... ment of hypophosphatemia . ( a ) Hypophosphatemia is a condition in which an abnormally low plasma level of phosphate occurs in the blood . This condition is not amenable to self- diagnosis or self - treatment . Treatment of this ...
55. lappuse
... ment drug products . Bismuth subnitrate Boric acid Pyridoxine hydrochloride Sulfur Tannic acid Topical starch Trolamine Zinc sulfate ( v ) Insect bite and sting drug products . Alcohol Alcohol , ethoxylated alkyl Ammonia solution ...
... ment drug products . Bismuth subnitrate Boric acid Pyridoxine hydrochloride Sulfur Tannic acid Topical starch Trolamine Zinc sulfate ( v ) Insect bite and sting drug products . Alcohol Alcohol , ethoxylated alkyl Ammonia solution ...
60. lappuse
... ment and / or prevention of malaria is regarded as a new drug within the meaning of section 201 ( p ) of the act , for which an approved application or ab- breviated application under section 505 of the act and part 314 of this chapter ...
... ment and / or prevention of malaria is regarded as a new drug within the meaning of section 201 ( p ) of the act , for which an approved application or ab- breviated application under section 505 of the act and part 314 of this chapter ...
63. lappuse
... ment is any use of a drug except for the use of a marketed drug in the course of medical practice . Contract research organization means a person that assumes , as an independent contractor with the sponsor , one or more of the ...
... ment is any use of a drug except for the use of a marketed drug in the course of medical practice . Contract research organization means a person that assumes , as an independent contractor with the sponsor , one or more of the ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning